Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01667627
Other study ID # TASMC-11-RD-0491-CTIL
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 2014
Est. completion date April 2015

Study information

Verified date May 2018
Source Tel-Aviv Sourasky Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

We present the study design of a clinical trial designed to assess the clinical effects of the multispecies probiotic combination "BIO-25" in IBS-D patients. To this aim the primary endpoints of the study will be improvement in abdominal pain and stool consistency. The study will also be designed and powered to investigate the effect of the probiotic BIO-25 on the putative inflammation-associated parameters related to microinflammation in IBS, using postulated improvements in Hs-CRP, and calprotectin as markers of that effect. Additional aims of the study will examine the possible effect of probiotic BIO-25 on the cholinergic status.


Description:

Probiotic treatment in IBS is safe and effective. Probiotics have been shown to improve the anti-inflammatory/proinflammatory ratio, and may also improve intestinal motility, and the bacterial composition of the intestines. There is a substantial body of evidence in support of the use of probiotics in IBS. Probiotics appear to be particularly effective in the reduction of abdominal bloating and discomfort. The strains of the multispecies probiotic combination (BIO-25 LR) were tested and found to be beneficial in well-designed studies of IBS patients. Patients with post-infectious IBS, as well as many patients with "classic" IBS, manifest a low-grade inflammatory state that may be associated with visceral hypersensitivity and impaired motility. Probiotics may suppress this low-grade inflammation. In a recent study we found that highly sensitive CRP (hs-CRP), a serum marker of micro-inflammation, was significantly higher in patients with diarrhea-predominant IBS than healthy controls, although within normal limits in both groups. Thus, hs-CRP may serve as a marker of this low-grade, sub-clinical inflammation. If treatment with probiotic reduces the degree of low-grade inflammation in IBS, the improvement may be reflected in reduced hs-CRP levels. This study can contribute to our understanding of the pathophysiology of IBS and provide further evidence for the effectiveness of probiotic in its treatment.


Recruitment information / eligibility

Status Completed
Enrollment 107
Est. completion date April 2015
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

A diagnosis of IBS-D according to the Rome III criteria, agreement to participate and the ability to sign an informed consent. Moreover, the definition of inclusion criteria is based on the FDA Draft Guidance for Clinical Evaluation of Products (add ref here). Over the two week run-in period:

- Pain Intensity: weekly average of worst abdominal pain in past 24 hours score of = 3.0 on a 0 (no pain at all) to 10 (worst possible pain) point scale

- Stool Consistency: =30% of days/week with at least one stool =6 using the Bristol Stool Score (BSS, Fig. 1) (ref).

Exclusion Criteria:

1) Hyperthyroidism, 2) celiac disease 3) pregnancy, 4) other gastrointestinal diagnoses that might interfere with the study (e.g. active peptic disease, inflammatory bowel disease), 5) a history of malignancy that might, to the best judgment of the doctor, interfere with the study, 6) any infectious or inflammatory disease within the last month, 7) active medically treated asthma, 8) baseline levels of HsCRP > 10mg/liter, 9) steroid treatment for any indication, 10) fecal incontinence, and 11) treatment with probiotics or antibiotics of any kind within the last 4 weeks, 11) Diabetes.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Bio-25
Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria. Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus.
Other:
Placebo
Identical placebo

Locations

Country Name City State
Israel Tel-Aviv Sourasky Medical Center Tel-Aviv Central Israel

Sponsors (1)

Lead Sponsor Collaborator
Tel-Aviv Sourasky Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Symptom relief (abdominal pain and stool consistency) Abdominal pain intensity, stool consistency, will be assessed by visual analogue scales (VAS) with scales from 0 (no symptom at all) to 10 (the worst possible symptom.
The definition of treatment responders is based on the FDA Draft Guidance for Clinical Evaluation of Products for Treatment of Irritable Bowel Syndrome.
A Pain Intensity Responder is a patient who experiences a 30% or greater decrease in the weekly average of worst abdominal pain in past 24 hours in the past 24 hours compared to baseline.
A Stool Consistency Responder is a patient who has a greater than 50% decrease in the number of days with at least one stool = type 6 using the Bristol Stool Scale (BSS).
A patient will be classified as an overall responder if they achieve the above improvement in pain intensity and stool consistency for at least 50 percent of the time.
8 weeks
Secondary Improvement in other specific IBS symptoms, i.e., gas and bloating, feeling of urgency Specific IBS symptoms, i.e., gas and bloating, feeling of urgency, will be assessed by visual analogue scales (VAS) with scales from 0 (no symptom at all) to 10 (the worst possible symptom). 8 weeks
Secondary Reduce hs-CRP levels Blood will be drawn from IBS-D patients after a 12-hour fast and will be analyzed for hs-CRP. 8 weeks
Secondary Improve the cholinergic status Plasma cholinesterase catalytic activity measurements will involve adaptation of a spectrophotometric method to a microtiter plate assay 8 weeks
Secondary Reduce calprotectin levels At the beginning and at the end of the treatment period, fecal samples will be obtained for the measurement of calprotectin levels.
The quantitative concentration of calprotectin will be determined by enzyme linked immunosorbent assay (ELISA).
8 weeks
See also
  Status Clinical Trial Phase
Completed NCT04677881 - Health Effects of Different Types of Bread N/A
Completed NCT02293343 - 24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance N/A
Completed NCT01717404 - Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C) Phase 1
Withdrawn NCT02313207 - Confocal Laser Endomicroscopy in IBS Patients N/A
Completed NCT02937506 - Patient Satisfaction With Propofol for Out Patient Colonoscopy Phase 4
Terminated NCT05579444 - Systems Biology of Gastrointestinal and Related Diseases
Completed NCT02419963 - Analyzing IBS to Identify Biomarkers and Microbiome Signatures N/A
Recruiting NCT06389851 - Effects of Tomato Consumption on Steatosis, Intestinal Function and Glucose and Lipid Metabolism in Subjects With NAFLD N/A
Recruiting NCT05815602 - Ebastine Versus Mebeverine in IBS Patients Phase 3
Completed NCT03482765 - A Study of Probiotics in IBS Subjects N/A
Completed NCT03986476 - The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome N/A
Recruiting NCT06275906 - Influence of a Mediterranean Diet Combined With a Physical Activity Intervention, on NAFLD and Inflammation Parameters. N/A
Not yet recruiting NCT05737277 - Gabapral in Pediatric IBS N/A
Active, not recruiting NCT05718505 - Comparison of the Atmo Motility Gas Capsule System to the Reference Standard N/A
Recruiting NCT06072287 - The Living With a Long-Term Condition Study
Completed NCT04953728 - Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C N/A
Completed NCT02681666 - Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome N/A
Completed NCT02981888 - Fecal Metabolome and the Intestinal Microbiota in Irritable Bowel Syndrome
Recruiting NCT01779765 - The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Phase 4
Completed NCT02009618 - The Effects of Rifaximin Therapy in Irritable Bowel Syndrome N/A